What Are the Predictors of Acute Kidney Injury in Children Admitted to Pediatrics Intensive Care Unit at Assiut University Children Hospital?

April 2, 2026 updated by: Ahmed Salama Salah, Assiut University

Predictors of Acute Kidneyinjury in Children Admitted to Pediatrics Intensive Care Unit at Assiut University ChildrenHospital

Identify the Predictors of Acute Kidney Injury in critically ill children admitted to PICU during one year

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Acute kidney injury (AKI) is defined by a sudden loss of excretory kidney function. AKI is part of a range of conditions summarized as acute kidney diseases and disorders (AKD), in which slow deterioration of kidney function or persistent kidney dysfunction is associated with an irreversible loss of kidney cells and nephrons, which can lead to chronic kidney disease AKI is determined by increased serum creatinine levels >0.3 mg/dl (a marker of kidney excretory function) and reduced urinary output <0.5 ml/Kg for more than 8 h (a quantitative marker of urine production) and is limited to a duration of 7 days and when lasts for>3months is referred to as chronic kidney disease (CKD).Acute kidney injury (AKI) is associated with poor outcome in critically ill children.The reported incidence rate of AKI in children admitted to pediatric intensive care units (PICUs) ranges from 8% and 89% worldwide. Stage 1 was identified in 24.24% of the AKI cases, stage 2 in 31.03% and stage 3 in 44.71%. The most prevalent cause of AKI was represented by prerenal AKI in 85.64% of the cases, followed by 12.16% renal causes respectively 2.18% postrenal causes.

Symptoms of an AKI come on suddenly, over the course of hours or days. They depend on the underlying cause, but some of the most common symptoms include hematuria, fever, rash, bloody diarrhea, severe vomiting, abdominal pain, no urine output or high urine output, pale skin. oedema, puffy eyes and detectable abdominal mass. stages of Acute Kidney Injury .A standardized definition of AKI was proposed by the Kidney Disease: ImprovIng Global Outcomes (KDIGO) AKI working group in 2012 and has been validated In pediatric populations subsequently. This definition identifies and stages AKI Based on changes in serum creatinine from baseline or urine output as detailed .

Stage 1 Serum creatinine increase by 1.5-1.9 times baseline within 7 days or increase by ≥0.3 mg/dL (26.5 μmol/L) within 48 hours Urine output is less than 0.5 mL/kg/h for 6 - 12 hours Stage 2 Serum creatinine increase by 2-2.9 times baseline Urine output is less than 0.5 mLkg/h for >12 hours Stage 3 Serum creatinine increase by ≥3 times baseline or increase to≥ 4 mg/dL (353.6 μmol/L) or renal replacement therapy initiation or in patients younger than 18 years decrease in estimated GFR to <35 mL/min/1.73 m2 Urine output is less than 0.3 ml/kg/h for ≥24 h or anuria for ≥12h There are many predisposing factors that lead to AKI for such as gastroenteritis, presence of infection, sepsis, shock, cardiac disease, mechanical ventilation hypoxia and coagulopathy are important predictors for AKI. Despite significant developments in the management of AKI, the overall mortality rate of patients with AKI has not improved dramatically. The most widely available studies deal primarily with AKI, reporting mortality rates between 11% and 63% in pediatric patients. Outcomes among children who develop acute kidney injury (AKI). Children who develop AKI while hospitalized are at risk for poorer short-and mid/long-term outcomes. Across both acute and critical care populations, AKI is associated with longer lengths of stay, non-recovery of baseline renal function, and chronic renal disease including proteinuria hypertension, and chronic kidney disease (CKD).

Study Type

Observational

Enrollment (Estimated)

100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

acute kidney injury in pediatrics from 1 month to 18years

Description

Inclusion Criteria:

  • All cases of acute kidney injury in pediatrics from 1 month to 18years who admitted to PICU Assiut University Children Hospital according to (KDIGO) AKI Staging criteria during the duration of the study.

Exclusion Criteria:

  • Neonates
  • patients above 18 years of age
  • patients with chronic kidney disease
  • patients with renal malformations

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of acute kidney injury (AKI) associated with sepsis and related clinical risk factors.
Time Frame: One year
Detection of clinical risk factors including sepsis, septic shock, pre-existing comorbidities, mechanical ventilation, and use of inotropes among hospitalized patients.
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

August 1, 2027

Study Registration Dates

First Submitted

April 2, 2026

First Submitted That Met QC Criteria

April 2, 2026

First Posted (Actual)

April 8, 2026

Study Record Updates

Last Update Posted (Actual)

April 8, 2026

Last Update Submitted That Met QC Criteria

April 2, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • AKI in ICU children

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on AKI

Clinical Trials on Clinical and laboratory assessment

Subscribe